Al Sulaiman Khalid, Alkofide Hadeel A, AlFaifi Mashael E, Aljohani Sarah S, Al Harthi Abdullah F, Alqahtani Rahaf A, Alanazi Ashwaq M, Nazer Lama H, Al Shaya Abdulrahman I, Aljuhani Ohoud
Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Saudi Pharm J. 2024 Jun;32(6):102094. doi: 10.1016/j.jsps.2024.102094. Epub 2024 May 11.
Septic shock is associated with systemic inflammatory response, hemodynamic instability, impaired sympathetic control, and the development of multiorgan dysfunction that requires vasopressor or inotropic support. The regulation of immune function in sepsis is complex and varies over time. However, activating Beta-2 receptors and blocking Beta-1 receptors reduces the proinflammatory response by influencing cytokine production. Evidence that supports the concomitant use of ultra short beta-blockers with inotropes and vasopressors in patients with septic shock is still limited. This study aimed to evaluate the use of ultra short beta-blockers and its impact on the ICU related outcomes such as mortality, length of stay, heart rate control, shock resolution, and vasopressors/inotropes requirements.
A systematic review and meta-analysis of randomized controlled trials including critically ill patients with septic shock who received inotropes and vasopressors. Patients who received either epinephrine or norepinephrine without beta-blockers "control group" were compared to patients who received ultra short beta-blockers concomitantly with either epinephrine or norepinephrine "Intervention group". MEDLINE and Embase databases were utilized to systematically search for studies investigating the use of ultra short beta-blockers in critically ill patients on either epinephrine or norepinephrine from inception to October 10, 2023. The primary outcome was the 28-day mortality. While, length of stay, heart rate control, and inotropes/ vasopressors requirements were considered secondary outcomes.
Among 47 potentially relevant studies, nine were included in the analysis. The 28-day mortality risk was lower in patients with septic shock who used ultra short beta-blockers concomitantly with either epinephrine or norepinephrine compared with the control group (RR (95%CI): 0.69 (0.53, 0.89), 2=26%;=0.24). In addition, heart rate was statistically significantly lower with a standardized mean difference (SMD) of -22.39 (95% CI: -24.71, -20.06) among the beta-blockers group than the control group. The SMD for hospital length of stay and the inotropes requirement were not statistically different between the two groups (SMD (95%CI): -0.57 (-2.77, 1.64), and SMD (95%CI): 0.08 (-0.02, 0.19), respectively).
The use of ultra short beta-blockers concomitantly with either epinephrine or norepinephrine in critically ill patients with septic shock was associated with better heart rate control and survival benefits without increment in the inotropes and vasopressors requirement.
脓毒性休克与全身炎症反应、血流动力学不稳定、交感神经控制受损以及需要血管升压药或正性肌力药支持的多器官功能障碍的发展有关。脓毒症中免疫功能的调节很复杂,且随时间变化。然而,激活β-2受体并阻断β-1受体会通过影响细胞因子产生来减少促炎反应。支持在脓毒性休克患者中同时使用超短效β受体阻滞剂与正性肌力药和血管升压药的证据仍然有限。本研究旨在评估超短效β受体阻滞剂的使用及其对重症监护病房(ICU)相关结局的影响,如死亡率、住院时间、心率控制、休克缓解以及血管升压药/正性肌力药需求。
对随机对照试验进行系统评价和荟萃分析,纳入接受正性肌力药和血管升压药的重症脓毒性休克患者。将未使用β受体阻滞剂的接受肾上腺素或去甲肾上腺素治疗的患者“对照组”与同时接受超短效β受体阻滞剂和肾上腺素或去甲肾上腺素治疗的患者“干预组”进行比较。利用MEDLINE和Embase数据库系统检索自数据库建立至2023年10月10日期间调查超短效β受体阻滞剂在接受肾上腺素或去甲肾上腺素治疗的重症患者中使用情况的研究。主要结局是28天死亡率。而住院时间、心率控制以及正性肌力药/血管升压药需求被视为次要结局。
在47项潜在相关研究中,9项被纳入分析。与对照组相比,同时使用超短效β受体阻滞剂和肾上腺素或去甲肾上腺素的脓毒性休克患者28天死亡风险更低(风险比(95%置信区间):0.69(0.53,0.89),I² = 26%;P = 0.24)。此外,β受体阻滞剂组的心率在统计学上显著更低,标准化均数差(SMD)为 -22.39(95%置信区间:-24.71,-20.06)。两组之间住院时间和正性肌力药需求的标准化均数差无统计学差异(分别为SMD(95%置信区间):-0.57(-2.77,1.64)和SMD(95%置信区间):0.08(-0.02,0.19))。
在重症脓毒性休克患者中同时使用超短效β受体阻滞剂与肾上腺素或去甲肾上腺素可带来更好的心率控制和生存获益,且不会增加正性肌力药和血管升压药的需求。